Download presentation
Presentation is loading. Please wait.
Published byPatience Montgomery Modified over 6 years ago
1
Future Directions in Myelofibrosis: Implications of Emerging Approaches
3
This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
4
Myeloproliferative Neoplasms
5
Diagnosis of Myelofibrosis
6
MYSEC-MF: A Molecular-Enriched Prognostic Model
7
Myelofibrosis
8
Factors Driving Therapy Choice in Myelofibrosis
9
Clinically Adjusted Treatment of Myelofibrosis
10
Treatment Algorithm for Anemia in MF
11
Treatment Is Dictated by Risk Category
12
MIPSS70 Risk Score: Variables Associated With Reduced OS
13
Indications of SCT in Myelofibrosis
14
JAK Inhibitors in Myelofibrosis
15
Impact on Disease Symptoms and QoL
16
COMFORT-II: Patient Disposition at 5 Years
17
JAK Inhibitors in Myelofibrosis
18
JAKARTA: Fedratinib in Myelofibrosis
19
Primary Endpoint: Spleen Response (ITT Population)
20
JAKARTA-2: Open-Label Study With Fedratinib
21
Fedratinib: Effective Second Line in MF — Results of JAKARTA 2
22
Review of Encephalopathy Cases
23
Pacritinib in MF: PERSIST Phase 3 Trials
24
SIMPLIFY-1: Primary Endpoint, Spleen; Secondary Endpoint, Reduction in Symptoms
25
SIMPLIFY-2: Primary Endpoint, SRR; Secondary Endpoint, TSS Response Rate
26
Non-JAK Inhibitors
27
Molecular and Histologic Remissions With Imetelstat
28
Pentraxin: Targeting Fibrosis
29
Sotatercept in MF
30
Long-Term Outcome of Patients With MPN-Associated Myelofibrosis Treated With Peg-Interferon α2a: FIM Study
31
Rationale for Drug Combination in MF
32
Preliminary Results of Ruxolitinib Combinations
33
JAK Inhibitor Plus Allografting
34
Preliminary Results of Ruxolitinib Combinations
35
Unmet Needs
36
How to Follow and Measure Efficacy
37
Immunotherapy
38
Conclusion
39
Abbreviations
40
Abbreviations (cont)
41
Abbreviations (cont)
42
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.